Clene Inc. (CLNN) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Clene Inc. is a clinical-stage pharmaceutical company developing clean-surfaced nanotechnology therapeutics for central nervous system disorders, including ALS, Multiple Sclerosis (MS), and Parkinson's disease. The company also generates limited revenue from dietary supplements via a related-party agreement with 4Life Research LLC. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $15,000 | $87,000 | $123,000 | $251,000 |
| Net Loss | $(8,777,000) | $(7,986,000) | $(16,947,000) | $(25,851,000) |
| Loss Per Share (Basic/Diluted) | $(0.85) | $(1.22) | $(1.77) | $(4.00) |
| Cash & Equivalents (End of Period) | $7,925,000 | N/A | N/A | N/A |
| Net Cash Used in Operating Activities (9M) | N/A | N/A | $(13,747,000) | $(16,461,000) |
| Total Debt (Notes & Convertible) | $17,045,000 | N/A | N/A | N/A |
| Accumulated Deficit | $(299,070,000) | N/A | N/A | N/A |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 83% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 51% year-to-date, driven by reduced product sales and royalty revenue from the 4Life agreement.
- Expense Reduction: Operating expenses decreased 28% in Q3 and 36% YTD compared to the prior year periods. This was achieved through cost-saving initiatives, including reduced personnel costs and lower legal fees.
- Net Loss Improvement: While the Q3 net loss increased slightly by 10% compared to Q3 2024, the YTD net loss improved significantly by 34% due to lower operating expenses and increased grant revenue recognized as a reduction of R&D costs.
- Debt Structure: The company issued new Senior Secured Convertible Promissory Notes (SSCP Notes) in December 2024 and August 2025, totaling approximately $11.5 million in principal, to refinance prior obligations and fund operations.
- Non-Cash Charges: Significant non-cash losses were recorded due to changes in the fair value of common stock warrant liabilities and derivative liabilities associated with the SSCP Notes.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date. The company expects to incur additional losses and does not have sufficient cash to sustain operations without additional financing.
- Liquidity Covenant: The company must maintain unrestricted cash and cash equivalents of at least $2.0 million to avoid acceleration of the 2024 SSCP Notes. As of September 30, 2025, cash was $7.9 million, meeting this requirement.
- Financing Plans: The company plans to raise capital through equity offerings (including its At-The-Market facility), debt financing, and potential collaborations. It has implemented cost-cutting measures, including staff reductions and delayed R&D programs.
- Clinical Outlook:
- ALS: Planning to submit a New Drug Application (NDA) under an accelerated approval pathway in Q1 2026, pending FDA feedback on biomarker data.
- MS: Announced positive Phase 2 results for REPAIR-MS showing increased brain NAD+/NADH ratios. Planning a Phase 3 study focusing on cognition.
- Parkinson's: Announced positive preclinical data in dopaminergic neuron models.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding the control environment, manual journal entries, and IT general controls. Remediation efforts are ongoing.
Investor Verification Checklist
- Verify the sufficiency of the $7.9 million cash balance against the projected burn rate and the $2.0 million debt covenant requirement.
- Confirm the status of the planned Q1 2026 NDA submission for CNM-Au8 in ALS and the FDA's response to recent data submissions.
- Assess the impact of the material weaknesses in internal controls on the reliability of future financial reporting.
- Monitor the company's ability to execute its equity financing plans (ATM facility) given current market conditions.
- Review the terms of the Senior Secured Convertible Promissory Notes, specifically the conversion features and potential dilution.